Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 75 of 808 entries
View as:

Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT00431210 Org: User:
Start: 02/28/07 End: 01/26/16 Due: 01/26/17

Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT00378209 Org: User:
Start: 08/31/06 End: 10/31/16 Due: 10/31/17

CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01191697 Org: User:
Start: 02/28/11 End: 07/31/25 Due: 07/31/26

Metronomic Low-Dose Cyclophosphamide and Methotrexate With or Without Bevacizumab in Treating Women With Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00083031 Org: User:
Start: 07/31/03 End: 08/31/09 Due: 08/31/10

Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM)

Phase: N/A Priority: Normal
NCT ID: NCT00422799 Org: User:
Start: 08/30/06 End: 10/09/15 Due: 10/09/16

SIGNAL:Identifying Behavioral Anomalies Using Smartphones to Improve Cancer Care

Phase: N/A Priority: Normal
NCT ID: NCT04368130 Org: User:
Start: 09/01/22 End: 09/01/23 Due: 09/01/24

Using Positron Emission Tomography to Evaluate the Effects of Bevacizumab on Intra-tumoral Pharmacokinetics of 5-fluorouracil in Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00165568 Org: User:
Start: 07/31/05 End: 10/31/06 Due: 10/31/07

High-Intensity Interval Exercise in Young Adult Survivors of Pediatric Brain Tumors: A Pilot Feasibility Study

Phase: N/A Priority: Normal
NCT ID: NCT05740839 Org: User:
Start: 12/04/23 End: 05/31/26 Due: 05/31/27

INTENT Pilot Study - Enhancing Adherence Intentions to Endocrine Therapy

Phase: N/A Priority: Normal
NCT ID: NCT06246084 Org: User:
Start: 02/15/24 End: 12/23/24 Due: 12/23/25

UNTIRE: Cancer-related Fatigue With Digital Treatment

Phase: N/A Priority: Normal
NCT ID: NCT05584540 Org: User:
Start: 01/30/25 End: 01/30/26 Due: 01/30/27

Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN

Phase: N/A Priority: Normal
NCT ID: NCT03085719 Org: User:
Start: 06/30/17 End: 10/31/27 Due: 10/31/28

Improving Cognitive Function Through High-intensity Interval Training in Breast Cancer Patients Undergoing Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT04724499 Org: User:
Start: 07/14/21 End: 06/15/26 Due: 06/15/27

Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03520790 Org: User:
Start: 12/05/18 End: 07/01/24 Due: 07/01/25

Smart Phone App Intervention In Young Adults With Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04119869 Org: User:
Start: 11/11/19 End: 06/29/20 Due: 06/29/21

ASP8374 + Cemiplimab in Recurrent Glioma

Phase: N/A Priority: Normal
NCT ID: NCT04826393 Org: User:
Start: 03/09/22 End: 06/30/25 Due: 06/30/26

RAD001 for Patients With Radioiodine Refractory Thyroid Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00936858 Org: User:
Start: 07/31/09 End: 02/27/20 Due: 02/27/21

LY3214996 in Patients With AML Who Are Not Candidates for Standard Therapy

Phase: N/A Priority: Normal
NCT ID: NCT04081259 Org: User:
Start: 07/15/20 End: 08/26/23 Due: 08/26/24

Combination Chemotherapy in Treating Patients With Stage IIB, Stage III, or Stage IV Cancer of the Nasopharynx

Phase: N/A Priority: Normal
NCT ID: NCT00004164 Org: User:
Start: 08/31/99 End: - Due: -

Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00006107 Org: User:
Start: 07/14/00 End: 07/03/04 Due: 07/03/05

Cisplatin + RT for Triple Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01674842 Org: User:
Start: 10/31/12 End: 06/08/21 Due: 06/08/22

Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma

Phase: N/A Priority: Normal
NCT ID: NCT00137826 Org: User:
Start: 02/29/04 End: 07/31/09 Due: 07/31/10

Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00520013 Org: User:
Start: 08/31/07 End: 11/30/13 Due: 11/30/14

Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing

Phase: N/A Priority: Normal
NCT ID: NCT06907797 Org: User:
Start: 04/01/25 End: 06/30/27 Due: 06/30/28

BKM120 For Triple Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01790932 Org: User:
Start: 06/30/12 End: 09/30/15 Due: 09/30/16

Dynamic Area Telethermometry (DAT) as an Imaging Modality in Patients With Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00165100 Org: User:
Start: 01/31/00 End: 10/31/02 Due: 10/31/03